The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP / TAZ activation
Open accessAbstract
The activation of transcriptional coactivators YAP and its paralog TAZ has been shown to promote resistance to anti‐cancer therapies. YAP / TAZ activity is tightly coupled to actin cytoskeleton architecture. However, the influence of actin remodeling on cancer drug resistance remains largely unexplored. Here, we report a pivotal role of actin remodeling in YAP / TAZ ‐dependent BRAF inhibitor resistance in BRAF V600E mutant melanoma cells. Melanoma cells resistant to the BRAF inhibitor PLX 4032 exhibit an increase in actin stress fiber formation, which appears to promote the nuclear accumulation of YAP / TAZ . Knockdown of YAP / TAZ reduces the viability of resistant melanoma cells, whereas overexpression of constitutively active YAP induces resistance. Moreover, inhibition of actin polymerization and actomyosin tension in melanoma cells suppresses both YAP / TAZ activation and PLX 4032 resistance. Our si RNA library screening identifies actin dynamics regulator TESK 1 as a novel vulnerable point of the YAP / TAZ ‐dependent resistance pathway. These results suggest that inhibition of actin remodeling is a potential strategy to suppress resistance in BRAF inhibitor therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Tensional homeostasis and the malignant phenotype
Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., Reinhart-King, C. A., Margulies, S. S., Dembo, M., Boettiger, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.010 · Cited by 3,941
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Local force and geometry sensing regulate cell functions
Vogel, V., & Sheetz, M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1890 · Cited by 2,328 · cited 1×
“Because actin cytoskeleton architecture and resulting mechanical properties impact on diverse aspects of cellular behavior (Vogel & Sheetz, 2006; Jaalouk & Lammerding, 2009), we hypothesized that actin remodeling in melanoma cells may contribute to the induction of adaptive resistance to BRAF…”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
A tense situation: forcing tumour progression
Butcher, D. T., Alliston, T., & Weaver, V. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2544 · Cited by 1,940
Aragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., & Piccolo, S. (2013) · Cell · doi:10.1016/j.cell.2013.07.042 · Cited by 1,651
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“…potential mechanisms of BRAF inhibitor resistance: EGFR upregulation driven by SOX10 loss (Girotti et al , 2013; Sun et al , 2014), acquired NRAS and MEK1 mutations (Van Allen et al , 2014), WNT5A upregulation (Anastas et al , 2014), and BRAF alternative splicing (Poulikakos et al , 2011).”
Jaalouk, D. E., & Lammerding, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2597 · Cited by 1,396 · cited 1×
“Because actin cytoskeleton architecture and resulting mechanical properties impact on diverse aspects of cellular behavior (Vogel & Sheetz, 2006; Jaalouk & Lammerding, 2009), we hypothesized that actin remodeling in melanoma cells may contribute to the induction of adaptive resistance to BRAF…”
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381
The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal
Zhao, B., Tumaneng, K., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2303 · Cited by 1,205
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145
Transduction of mechanical and cytoskeletal cues by YAP and TAZ
Halder, G., Dupont, S., & Piccolo, S. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3416 · Cited by 985
Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement
Sanz-Moreno, V., Gadea, G., Ahn, J., Paterson, H., Marra, P., Pinner, S., Sahai, E., & Marshall, C. J. (2008) · Cell · doi:10.1016/j.cell.2008.09.043 · Cited by 959
Linking actin dynamics and gene transcription to drive cellular motile functions
Olson, E. N., & Nordheim, A. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2890 · Cited by 958
Zhou, D., Conrad, C., Xia, F., Park, J.-S., Payer, B., Yin, Y., Lauwers, G. Y., Thasler, W., Lee, J. T., Avruch, J., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.026 · Cited by 913
Self-citationThe Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., Place, C. S., Taylor-Weiner, A., Whittaker, S., Kryukov, G. V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0617 · Cited by 912
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis
Zhao, B., Li, L., Wang, L., Wang, C.-Y., Yu, J., & Guan, K.-L. (2012) · Genes & Development · doi:10.1101/gad.173435.111 · Cited by 793
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Self-citationMicropatterning as a tool to decipher cell morphogenesis and functions
Théry, M. (2010) · Journal of Cell Science · doi:10.1242/jcs.075150 · Cited by 730 · cited 1×
“We restricted the spreading area of resistant cells, using adhesive micropatterns (Thery, 2010).”
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 4×
“In line with our results, a recently published study also demonstrated that E2F1 and YAP cooperate to enable bypass of oncogenic KRAS addiction (Kapoor et al , 2014).”
InfluentialAngiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
Zhao, B., Li, L., Lu, Q., Wang, L. H., Liu, C.-Y., Lei, Q., & Guan, K.-L. (2011) · Genes & Development · doi:10.1101/gad.2000111 · Cited by 665
Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M. R., Ksander, B. R., Merlino, G., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 563
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
Sahai, E. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.755 · Cited by 384
Girotti, M. R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., Zambon, A., Sinclair, J., Hayes, A., Gore, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0386 · Cited by 382
A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2884 · Cited by 294
Angiomotins link F-actin architecture to Hippo pathway signaling
Mana-Capelli, S., Paramasivam, M., Dutta, S., & McCollum, D. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-11-0701 · Cited by 206
Kim, J., Jo, H., Hong, H., Kim, M. H., Kim, J. M., Lee, J.-K., Heo, W. D., & Kim, J. (2015) · Nature Communications · doi:10.1038/ncomms7781 · Cited by 202
Self-citationResistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H., Xu, L., Higgins, B., Kolinsky, K., Packman, K., Kim, M. J., Trunzer, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 179
Self-citationWNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T., Rizos, H., Long, G. V., von Euw, E. M., Yang, P.-T., Chen, H.-W., Haydu, L., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 176
Pro-Invasive Activity of the Hippo Pathway Effectors YAP and TAZ in Cutaneous Melanoma
Nallet-Staub, F., Marsaud, V., Li, L., Gilbert, C., Dodier, S., Bataille, V. A., Sudol, M., Herlyn, M., & Mauviel, A. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.319 · Cited by 150
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Nguyen, T. V., Sleiman, M., Moriarty, T., Herrick, W. G., & Peyton, S. R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.058 · Cited by 143
Sánchez‐Laorden, B. L., Virós, A., Girotti, M. R., Pedersen, M., Saturno, G., Zambon, A., Niculescu‐Duvaz, D., Turajlic, S., Hayes, A. J., Gore, M. E., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004815 · Cited by 131
B-Raf Acts via the ROCKII/LIMK/Cofilin Pathway To Maintain Actin Stress Fibers in Fibroblasts
Pritchard, C. A., Hayes, L., Wojnowski, L., Zimmer, A., Marais, R., & Norman, J. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5937-5952.2004 · Cited by 105
The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells
Sharma, S., Santiskulvong, C., Rao, J., Gimzewski, J. K., & Dorigo, O. (2014) · Integrative Biology · doi:10.1039/c3ib40246k · Cited by 88
Sakurai, K., Talukdar, I., Patil, V. S., Dang, J. W., Li, Z., Chang, K., Lu, C., Delorme, V., DerMardirossian, C. M., Anderson, K., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.03.001 · Cited by 68
Mutual regulation between Hippo signaling and actin cytoskeleton
Matsui, Y., & Lai, Z.-C. (2013) · Protein & Cell · doi:10.1007/s13238-013-3084-z · Cited by 49
TransFind--predicting transcriptional regulators for gene sets
Kiełbasa, S. M., Klein, H., Roider, H. G., Vingron, M., & Blüthgen, N. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq438 · Cited by 39
Cited by
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
Mechanobiology of YAP and TAZ in physiology and disease
Panciera, T., Azzolin, L., Cordenonsi, M., & Piccolo, S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.87 · Cited by 1,461
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Targeting FAK in anticancer combination therapies
Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 384
YAP and TAZ: a signalling hub of the tumour microenvironment
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0168-y · Cited by 381
Metadata
- Authors
- Kim, M. H., Kim, J., Hong, H., Lee, S., Lee, J., Jung, E., & Kim, J.
- Venue
- The EMBO Journal
- Published
- 2015-12-14
- Volume
- 35
- Issue
- 5
- Pages
- 462-478
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W2197806847
- Cited by
- 265
- References
- 49
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.